These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27914740)

  • 21. Reducing respiratory syncytial virus (RSV) hospitalization in a lower-income country by vaccinating mothers-to-be and their households.
    Brand SP; Munywoki P; Walumbe D; Keeling MJ; Nokes DJ
    Elife; 2020 Mar; 9():. PubMed ID: 32216871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.
    Jorquera PA; Anderson L; Tripp RA
    Expert Rev Vaccines; 2016; 15(2):173-87. PubMed ID: 26641318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats.
    Grieves JL; Yin Z; Garcia-Sastre A; Mena I; Peeples ME; Risman HP; Federman H; Sandoval MJ; Durbin RK; Durbin JE
    Vaccine; 2018 Jun; 36(26):3842-3852. PubMed ID: 29779923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K; Wu H
    Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the development of subunit-based RSV vaccines.
    Jaberolansar N; Toth I; Young PR; Skwarczynski M
    Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology.
    Yang J; Ma C; Zhao Y; Fan A; Zou X; Pan Z
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model.
    Van Effelterre T; Hens N; White LJ; Gravenstein S; Bastian AR; Buyukkaramikli N; Cheng CY; Hartnett J; Krishnarajah G; Weber K; Pastor LH
    Clin Infect Dis; 2023 Aug; 77(3):480-489. PubMed ID: 36949605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of a neonatal mouse model to study respiratory syncytial virus infections.
    Cormier SA; You D; Honnegowda S
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1371-80. PubMed ID: 21133663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of truncated G protein delivered by live attenuated Salmonella as a vaccine against respiratory syncytial virus.
    Tian P; Xu D; Huang Z; Meng F; Fu J; Wei H; Chen T
    Microb Pathog; 2018 Feb; 115():299-303. PubMed ID: 29306006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.
    Groothuis JR; Hoopes JM; Jessie VG
    Adv Ther; 2011 Feb; 28(2):91-109. PubMed ID: 21318606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.